CAN
VRTX icon

Cetera Advisor Networks’s Vertex Pharmaceuticals VRTX Stock Holding History

Cetera Advisor Networks’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$9.47M Buy
22,650
+9,463
+72% +$4M 0.05% 392
2023
Q4 		$5.37M Buy
13,187
+674
+5% +$249K 0.03% 545
2023
Q3 		$4.35M Buy
12,513
+1,968
+19% +$688K 0.03% 569
2023
Q2 		$3.71M Sell
10,545
-3,164
-23% -$1.07M 0.03% 620
2023
Q1 		$4.32M Buy
13,709
+2,190
+19% +$657K 0.03% 542
2022
Q4 		$3.33M Buy
11,519
+4,488
+64% +$1.37M 0.03% 602
2022
Q3 		$2.04M Buy
7,031
+374
+6% +$108K 0.03% 584
2022
Q2 		$1.88M Buy
6,657
+170
+3% +$45.5K 0.02% 613
2022
Q1 		$1.69M Buy
6,487
+1,904
+42% +$452K 0.02% 677
2021
Q4 		$1.01M Buy
4,583
+381
+9% +$74.1K 0.01% 901
2021
Q3 		$762K Buy
4,202
+152
+4% +$29.7K 0.01% 970
2021
Q2 		$817K Buy
4,050
+613
+18% +$128K 0.01% 917
2021
Q1 		$739K Sell
3,437
-51
-1% -$11.2K 0.02% 705
2020
Q4 		$824K Sell
3,488
-29
-0.8% -$6.65K 0.02% 603
2020
Q3 		$957K Sell
3,517
-474
-12% -$131K 0.02% 492
2020
Q2 		$1.16M Buy
3,991
+345
+9% +$93.5K 0.03% 423
2020
Q1 		$868K Buy
3,646
+1
+0% +$229 0.03% 444
2019
Q4 		$800K Buy
3,645
+634
+21% +$128K 0.02% 568
2019
Q3 		$513K Buy
3,011
+321
+12% +$56.8K 0.02% 694
2019
Q2 		$490K Buy
2,690
+428
+19% +$74.8K 0.02% 688
2019
Q1 		$413K Buy
2,262
+748
+49% +$138K 0.01% 733
2018
Q4 		$251K Sell
1,514
-1,532
-50% -$265K 0.01% 839
2018
Q3 		$589K Buy
+3,046
New +$542K 0.02% 582
2018
Q2 		– Sell
-1,830
Closed -$299K – 967
2018
Q1 		$299K Buy
1,830
+64
+4% +$10.5K 0.01% 667
2017
Q4 		$263K Buy
1,766
+300
+20% +$44.4K 0.01% 796
2017
Q3 		$222K Sell
1,466
-115
-7% -$17.3K 0.01% 806
2017
Q2 		$207K Buy
+1,581
New +$190K 0.01% 839
2016
Q4 		– Sell
-2,545
Closed -$222K – 1014
2016
Q3 		$222K Buy
+2,545
New +$241K 0.01% 895

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Cetera Advisor Networks's VRTX Position: Q1 2024 in Review

Cetera Advisor Networks increased its Vertex Pharmaceuticals (VRTX) stake by 72% in Q1 2024, buying an estimated $4M and bringing the position to 22,650 shares worth $9.47M. The position accounts for 0.05% of the portfolio, ranked #392.

Cetera Advisor Networks first reported a position in VRTX in Q3 2016 and has held it in 28 quarters since. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Cetera Advisor Networks held 22,650 shares of Vertex Pharmaceuticals worth $9.47M as of Q1 2024.
  • Cetera Advisor Networks bought 9,463 Vertex Pharmaceuticals shares in Q1 2024, an estimated $4M.
  • Vertex Pharmaceuticals made up 0.05% of Cetera Advisor Networks's portfolio in Q1 2024, its #392 holding.
  • Cetera Advisor Networks first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 28 quarters since.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.